Discover
ADIL
Adial Pharmaceuticals, Inc.
4.22
9 x 4.14
2 x 4.30
bid
ask
+
0.01
0.24%
12:26 PM
timesize
| Ytd | -23.27% | |
| 1y | -54.38% |
4.04
day range
4.30
1.31
52 week range
10.75
| Open | 4.16 | Prev Close | 4.21 | Low | 4.04 | High | 4.30 | Mkt Cap | 4.05M |
| Vol | 8.46K | Avg Vol | 458.67K | EPS | -5.47 | P/E | -0.77 | Forward P/E | -0.79 |
| Beta | 1.39 | Short Ratio | 0.65 | Inst. Own | 3.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.86 | 200-d Avg | 4.00 | 1yr Est | 7.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.5 | -0.38 | 0.12 | 24.00% |
| 2024-08-13 | 2024-06 | -0.39 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.39 | -0.59 | -0.2 | -51.28% |
| 2024-05-14 | 2024-03 | -0.51 | -0.68 | -0.17 | -33.33% |
| 2024-05-14 | 2024-03 | -0.51 | N/A | N/A | N/A |
| 2024-04-04 | 2023-12 | -0.89 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | Rodman & Renshaw | Upgrade | Buy |
Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-22 | CLAIBORNE CARY J | Chief Executive Officer | 1.52M | Stock Award(Grant) |
| 2023-09-28 | SCHUYLER KEVIN | Director | 6.59K | Purchase |
| 2023-05-22 | STILLEY WILLIAM B. III | Director | 1.26M | Stock Award(Grant) |
| 2023-05-22 | TRULUCK JOSEPH | Chief Financial Officer | 265.14K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Manchester Capital Management, LLC | 48.10K | 50.50K | 0.75% |
| 2024-09-29 | Geode Capital Management, LLC | 45.47K | 47.74K | 0.71% |
| 2024-09-29 | Citadel Advisors Llc | 33.27K | 34.93K | 0.52% |
| 2024-09-29 | Blackrock Inc. | 27.77K | 29.16K | 0.43% |
| 2024-09-29 | Two Sigma Securities, LLC | 27.12K | 28.47K | 0.42% |
| 2024-09-29 | UBS Group AG | 4.40K | 4.62K | 0.07% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 35.14K | 36.90K | 0.55% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 9.36K | 9.83K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 9.16K | 9.62K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 7.75K | 8.14K | 0.12% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2026-02-06 |
| 1 : 25 | 2023-08-07 |